Jan. 13, 2026 at 2:03 PM ET5 min read

Twist Bioscience Surges with Impressive Q1 Revenue and Raised Price Targets

Tim BohenAvatar
Written by Tim Bohen Reviewed by Ben Sturgill Fact-checked by Ellis Hobbs

Twist Bioscience Corporation stocks have been trading up by 7.37 percent amidst positive investor sentiment and strategic growth updates.

Key Takeaways

  • Unaudited Q1 revenue of Twist Bioscience hits $103.7M, surpassing projections of $100.32M, reflecting a significant 17% year-over-year growth.
  • TD Cowen and Evercore ISI increased TWST’s price targets to $43 and $42, respectively, underlining positive investor sentiment and the prospect for sector recovery in 2026.
  • Twist Bioscience’s stock witnessed a substantial rally due to robust DNA Synthesis and NGS Applications performance, further fueled by analyst optimism.
  • Preliminary fiscal 2026 results exhibit a promising start with comprehensive financial disclosure expected on Feb 2, 2026.
  • Participation in the J.P. Morgan 2026 Healthcare Conference highlights expansion aspirations, affirming its leadership in synthetic DNA tools.

Candlestick Chart

Live Update At 14:02:11 EST: On Tuesday, January 13, 2026 Twist Bioscience Corporation stock [NASDAQ: TWST] is trending up by 7.37%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Twist Bioscience, reaching new heights, reported an unaudited Q1 fiscal 2026 revenue of $103.7M, which is $3.38M above analyst expectations. This financial triumph is attributed to its core offerings – DNA Synthesis, Protein Solutions, and NGS (Next-Generation Sequencing) Applications. Notably, NGS Applications witnessed an 18% revenue surge, excluding one large transitioning customer. As the market increasingly recognizes Twist as a pivotal player in synthetic biology, its stock displayed impressive volatility, closing at $40.845 on Jan 13, 2026.

Key financial ratios highlight its journey of growth amid challenges. Despite negative margins (-33.9% EBIT and -20.63% profit margins), dominant leverage with a debt-to-equity ratio of just 0.19 fosters faith in its long-term capacity to handle financial headwinds. The robust cash position, bolstered by strategic investments exceeding $23M, indicates disciplined capital management, propelling TWST’s ambitions into the future.

Stock Dynamics: Analyzing Positive Market Reactions

Twist Bioscience’s stock, cementing its role amidst biotech’s early 2026 rally, continues riding high on optimistic sentiments. TD Cowen’s and Evercore ISI’s recent hikes in TWST’s price targets have set the scene for renewed interest. Both price targets paint a brighter picture, suggesting expectations of a trend reversal in 2026 that encourages bolstered investor confidence and broader sector recovery. Enhanced price targets signal an alignment of market growth with Twist’s business strategies, reaffirming operational resilience despite previous economic deterrents.

Each upward reevaluation resonates with robust product verticals and impactful market advocacy. By aligning capital steeped in technological innovation, Twist Bioscience crafts a compelling narrative of growth, increasingly drawing investor and stakeholder admiration. Through astute alliances and tackling policy shifts, Twist seamlessly navigates the intricate landscapes of life sciences, making strides in both diagnostics and solutions applications.

The Strategic Path Forward

Looking ahead, Twist Bioscience eagerly enters the J.P. Morgan 2026 Healthcare Conference with eyes set on newfound partnerships. Expanding its horizons by showcasing groundbreaking advancements, the conference presents an empowering platform to solidify its industry dominance. The anticipated exposure not only amplifies its technological prowess but also reinforces its commitment to transforming synthetic DNA tools.

Hands-on engagement at the live event helps forge strategic alliances, enabling potential commercial synergies that leverage on Twist’s core capabilities. Industry observers widely tout these public interactions to mold future prospects, tuition an influx of investor interest and consideration of new opportunities to broaden the company’s market reach.

Twist Bioscience’s roadmap does not solely rely on quantitative victories alone. The poised ability to assume risks and secure innovative triumphs precipitates a domino effect that drives momentum with precision. NGS applications and assays are modern-day retools, emboldened by high scalability and low costs, pacing Twist Bioscience leaps in genomics and synthetic biology.

Conclusion

Twist Bioscience, through proactive leadership and sound operational ingenuity, is a testament to enduring market confidence amid evolving challenges. Strong revenue growth coupled with increasing price targets reflect trader faith in the company’s resilient strategies. In harnessing avenues such as the J.P. Morgan Conference and reaffirmed consumer trust, Twist Bioscience continues crafting a legacy of adaptive innovation. As Tim Bohen, lead trainer with StocksToTrade says, “If you’re still guessing at the end of your analysis, it’s probably not a trade worth taking,” but with Twist Bioscience setting benchmarks in its trajectory, traders feel assured of their strategies. The company’s evolving arc underpins a thriving future that advances the science of better living.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

The Game is Rigged

But Our Algo Has Leveled the Playing Field

Sign up for access to institutional grade tools and insights – free of charge

By entering your phone number and clicking Submit below, you provide your binding electronic signature and express written consent for StocksToTrade.com to call and text you at this number with educational info, including possibly using automated technology and AI, and outside of normal messaging hours. Consent not a condition of purchase as you can call/email us directly instead. Msg frequency varies and message and data rates may apply. Reply STOP to opt-out. Reply HELP for help.